Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI atai Life Sciences	$2.48 +6.4%	$1.85	$1.03 ▼ $2.64	$496.84M	1.47	1.72 million shs	3.94 million shs
CTNM Contineum Therapeutics	$4.76 +30.4%	$4.16	$3.35 ▼ $22.00	$123.14M	0.52	85,249 shs	297,181 shs
MREO Mereo BioPharma Group	$2.85 -0.7%	$2.45	$1.58 ▼ $5.02	$453.15M	0.48	1.09 million shs	1.38 million shs
PGEN Precigen	$1.45 -2.7%	$1.43	$0.65 ▼ $2.17	$428.01M	1.85	1.37 million shs	2.11 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI atai Life Sciences	0.00%	+17.54%	+20.39%	+57.96%	+85.07%
CTNM Contineum Therapeutics	0.00%	+7.45%	+33.33%	-38.66%	-74.39%
MREO Mereo BioPharma Group	0.00%	+3.26%	+27.23%	+14.46%	-28.39%
PGEN Precigen	0.00%	-4.61%	+5.84%	-20.33%	-5.84%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATAI atai Life Sciences	2.8032 of 5 stars	3.7	3.0	0.0	2.4	1.7	0.6
CTNM Contineum Therapeutics	2.7591 of 5 stars	3.6	3.0	0.0	2.0	0.8	1.3
MREO Mereo BioPharma Group	1.2104 of 5 stars	3.6	1.0	0.0	0.0	1.7	0.0
PGEN Precigen	3.6677 of 5 stars	3.5	1.0	4.7	1.1	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI atai Life Sciences	3.33	Buy	$8.67	249.46% Upside
CTNM Contineum Therapeutics	3.17	Buy	$22.50	372.69% Upside
MREO Mereo BioPharma Group	3.20	Buy	$7.60	166.67% Upside
PGEN Precigen	3.00	Buy	$6.00	313.79% Upside

Current Analyst Ratings Breakdown

Latest CTNM, PGEN, ATAI, and MREO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/12/2025	PGEN Precigen	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$6.00
5/20/2025	ATAI atai Life Sciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$5.00
5/20/2025	ATAI atai Life Sciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/19/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00
5/15/2025	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $31.00
5/15/2025	PGEN Precigen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
5/13/2025	ATAI atai Life Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/13/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
4/9/2025	MREO Mereo BioPharma Group	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
3/27/2025	MREO Mereo BioPharma Group	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$7.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI atai Life Sciences	$310K	1,602.72	N/A	N/A	$0.69 per share	3.59
CTNM Contineum Therapeutics	$50M	2.46	N/A	N/A	$7.66 per share	0.62
MREO Mereo BioPharma Group	$10M	45.32	N/A	N/A	$0.39 per share	7.31
PGEN Precigen	$3.92M	109.19	N/A	N/A	$0.13 per share	11.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI atai Life Sciences	-$149.27M	-$0.91	N/A	N/A	N/A	N/A	-102.10%	-77.55%	8/12/2025 (Estimated)
CTNM Contineum Therapeutics	-$42.26M	-$1.97	N/A	N/A	N/A	N/A	-24.59%	-23.49%	8/12/2025 (Estimated)
MREO Mereo BioPharma Group	-$43.25M	-$0.07	N/A	N/A	N/A	N/A	-69.33%	-57.27%	8/12/2025 (Estimated)
PGEN Precigen	-$126.24M	-$0.56	N/A	N/A	N/A	-3,728.87%	-279.20%	-79.74%	8/13/2025 (Estimated)

Latest CTNM, PGEN, ATAI, and MREO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	ATAI atai Life Sciences	-$0.19	-$0.15	+$0.04	-$0.15	N/A	$1.56 million
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/14/2025	Q1 2025	PGEN Precigen	-$0.08	-$0.07	+$0.01	-$0.18	$0.50 million	$1.34 million
5/13/2025	Q1 2025	MREO Mereo BioPharma Group	-$0.01	-$0.02	-$0.01	-$0.02	$72.50 million	N/A
3/26/2025	Q4 2024	MREO Mereo BioPharma Group	$0.02	-$0.01	-$0.03	-$0.01	$72.50 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI atai Life Sciences	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
MREO Mereo BioPharma Group	N/A	N/A	N/A	N/A	N/A
PGEN Precigen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI atai Life Sciences	0.08	4.07	4.07
CTNM Contineum Therapeutics	N/A	21.47	21.47
MREO Mereo BioPharma Group	N/A	8.92	8.92
PGEN Precigen	N/A	3.53	3.53

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI atai Life Sciences	28.41%
CTNM Contineum Therapeutics	N/A
MREO Mereo BioPharma Group	62.83%
PGEN Precigen	33.51%

Insider Ownership

Company	Insider Ownership
ATAI atai Life Sciences	26.80%
CTNM Contineum Therapeutics	11.30%
MREO Mereo BioPharma Group	5.50%
PGEN Precigen	47.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI atai Life Sciences	80	200.34 million	146.65 million	Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
MREO Mereo BioPharma Group	40	159.00 million	150.26 million	Optionable
PGEN Precigen	190	295.18 million	156.15 million	Optionable

CTNM, PGEN, ATAI, and MREO Headlines

Recent News About These Companies

JMP Securities Reaffirms Market Outperform Rating for Precigen (NASDAQ:PGEN)

June 14, 2025 | americanbankingnews.com

Cantor Fitzgerald Weighs in on Precigen FY2026 Earnings

June 13, 2025 | americanbankingnews.com

Precigen (NASDAQ:PGEN) Earns Market Outperform Rating from JMP Securities

June 12, 2025 | marketbeat.com

Precigen, Inc.'s (NASDAQ:PGEN) market cap touched US$455m last week, benefiting both private equity firms who own 33% as well as institutions

June 12, 2025 | finance.yahoo.com

Cantor Fitzgerald Estimates Precigen FY2026 Earnings

June 11, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Sells 792,731 Shares of Precigen, Inc. (NASDAQ:PGEN)

May 27, 2025 | marketbeat.com

Precigen (NASDAQ:PGEN) Downgraded to "Sell" Rating by Wall Street Zen

May 26, 2025 | marketbeat.com

J.P. Morgan Sticks to Its Sell Rating for Precigen (PGEN)

May 20, 2025 | theglobeandmail.com

Precigen, Inc.: Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 18, 2025 | finanznachrichten.de

Cantor Fitzgerald maintains Overweight on Precigen stock

May 17, 2025 | uk.investing.com

Precigen Reports First Quarter 2025 Financial Results and Business Updates

May 14, 2025 | prnewswire.com

Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th

April 16, 2025 | prnewswire.com

Is Precigen (PGEN) The Hot Biotech Stock Under $5?

March 27, 2025 | msn.com

Precigen options imply 20.1% move in share price post-earnings

March 20, 2025 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Edwards Lifesciences (EW)

March 20, 2025 | markets.businessinsider.com

4PGEN : Expert Outlook: Precigen Through The Eyes Of 4 Analysts

March 20, 2025 | benzinga.com

Precigen, Inc.: Precigen Reports Full Year 2024 Financial Results and Business Updates

March 20, 2025 | finanznachrichten.de

Precigen Reports Progress and Financial Results for 2024

March 19, 2025 | tipranks.com

Precigen, Inc. (PGEN) Q4 2024 Earnings Call Transcript

March 19, 2025 | seekingalpha.com

Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates

March 19, 2025 | zacks.com

Precigen Reports Full Year 2024 Financial Results and Business Updates

March 19, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CTNM, PGEN, ATAI, and MREO Company Descriptions

atai Life Sciences NASDAQ:ATAI

$2.48 +0.15 (+6.44%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.48 +0.00 (+0.16%)

As of 06/20/2025 07:59 PM Eastern

Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Contineum Therapeutics NASDAQ:CTNM

$4.76 +1.11 (+30.41%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$4.86 +0.11 (+2.21%)

As of 06/20/2025 07:49 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Mereo BioPharma Group NASDAQ:MREO

$2.85 -0.02 (-0.70%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$2.94 +0.09 (+3.33%)

As of 06/20/2025 07:34 PM Eastern

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Precigen NASDAQ:PGEN

$1.45 -0.04 (-2.68%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.45 0.00 (0.00%)

As of 06/20/2025 06:48 PM Eastern

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time